Study Title | A Phase I/II Study of the Oral RET inhibitor LOXO 292 in Paediatric patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumours |
---|---|
Protocol ID | LOXO-RET-18036 |
Disease (Sub Disease) | Brain and Spinal Tumours |
Diagnosis Stage | Relapse/ refractory |
Location | NSW / VIC |
Sponsor | Loxo Oncology, Inc. |
Collaborators | Eli Lilly and Company |
Links | https://clinicaltrials.gov/ct2/show/NCT03899792 |
Trial Status | Open |
Trial Open Date | 01/07/2019 |
Sites | Sydney Children's Hospital / Royal Children's Hospital |
Study Type | Treatment |
Phase | Phase 1/2 |
Age Eligibility | 6 months to 21 years |
International registry ID's | NCT03899792 |